Nurix Therapeutics Analyst Ratings
Nurix Therapeutics' Promising Outlook: Buy Rating Affirmed Amidst Strategic Development and Market Positioning
Nurix Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED), Cochlear Limited (OtherCHEOF) and Nurix Therapeutics (NRIX)
Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL), Biogen (BIIB) and Nurix Therapeutics (NRIX)
Nurix Therapeutics: Sustained Buy Rating Amidst Financial Reassessment and Promising Clinical Milestones
Buy Rating Affirmed on Nurix Therapeutics Amid Anticipated Clinical Advancements and Competitive Edge
Nurix Therapeutics Analyst Ratings
Analysts Conflicted on These Healthcare Names: Ultragenyx Pharmaceutical (RARE), Nurix Therapeutics (NRIX) and AMN Healthcare Services (AMN)
Barclays Releases a Buy Rating on Nurix Therapeutics (NRIX)
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS) and Nurix Therapeutics (NRIX)
Nurix Therapeutics: A Buy Rating With Promising Growth in the I&I Sector
Nurix Therapeutics Analyst Ratings
Nurix Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX) and Regeneron (REGN)
Nurix Therapeutics' NX-5948: A Buy Rating for the Emerging CLL Treatment Contender
Piper Sandler Remains a Buy on Nurix Therapeutics (NRIX)
Strong Buy Rating for Nurix Therapeutics Backed by Promising Clinical Data and Market Potential
Nurix Therapeutics (NRIX) Receives a Buy From Piper Sandler
Analysts Conflicted on These Healthcare Names: LivaNova (LIVN), Immutep (IMMP) and Nurix Therapeutics (NRIX)
No Data